Deutsche Bank Maintains Buy on Intuit, Raises Price Target to $780
Deutsche Bank analyst Brad Zelnick maintains Intuit (NASDAQ:INTU) with a Buy and raises the price target from $700 to $780.
Mid-Morning Market Update: Markets Mixed; Foot Locker Profit Beats Views
Following the market opening Friday, the Dow traded down 0.66% to 35,634.40 while the NASDAQ rose 0.54% to 16,079.51. The S&P also fell, dropping 0.03% to 4,703.27.
Morgan Stanley Maintains Overweight on Intuit, Raises Price Target to $720
Morgan Stanley analyst Keith Weiss maintains Intuit (NASDAQ:INTU) with a Overweight and raises the price target from $715 to $720.
Analysts Lift Price Targets On Intuit Post Q1 Success; See Up To 34% Upside
Analysts bumped up price targets on
Mizuho Maintains Buy on Intuit, Raises Price Target to $730
Mizuho analyst Siti Panigrahi maintains Intuit (NASDAQ:INTU) with a Buy and raises the price target from $640 to $730.
5 Stocks To Watch For November 19, 2021
Some of the stocks that may grab investor focus today are:
Wall Street expects Foot Locker, Inc. (NYSE: FL) to report quarterly earnings at $1.37 per share on revenue of $2.12 billion before the opening bell. Foot Locker shares rose 3.2% to $59.40 in after-hours trading.
Intuit’s Earnings Outlook
Intuit (NASDAQ:INTU) is set to give its latest quarterly earnings report on Thursday, 2021-11-18. Here's what investors need to know before the announcement.
Analysts estimate that Intuit will likely report an Earnings Per Share (EPS) of $0.99
Cathie Wood’s ARK Invest Posts Fund Sales For Monday, Nov. 15, 2021: Z, LMT, GOOG, NET, U, CLLS, CDXS, TAK, VEEV, REGN, INTU, OPEN
Zillow Group (Z)
Lockheed Martin (LMT)
Alphabet (GOOG)
Cloudflare (NET)
Unity Software (U)
Cellectis (CLLS)
Codexis (CDXS)
Takeda Pharmaceutical Co (TAK)
Veeva Systems (VEEV)
Regeneron Pharmaceuticals
Analyst Ratings For Intuit
Over the past 3 months, 14 analysts have published their opinion on Intuit (NASDAQ:INTU) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.